Skip to main content
. 2021 Jan 12;187:105015. doi: 10.1016/j.antiviral.2021.105015

Fig. 6.

Fig. 6

The STING agonist exhibits anti-SARS-CoV-2 ability on MucilAir™. (A) The diagram of assay procedure. (B–C) MucilAir™ were infected with SARS-CoV-2 at an MOI 0.1 at apical cell, followed by treatment with indicated concentrations of compounds for 48 h and 72 h. At indicated time point, (B) SARS-CoV-2 viral RNA quantification and (C) transepithelial electrical resistance (TEER) assay were performed for treatment of diABZI or RDV. The data are presented as the means ± SD of triplicate samples from one experiment and are representative of at least three independent experiments. *P < 0.05, **P < 0.01.